WEEKLY INJECTION · GLP-1
Wegovy®
Semaglutide Inj 0.25–2.4 mg
15%
avg. body weight lost in trials
Semaglutide mimics the natural GLP-1 hormone, binding to receptors in the pancreas, stomach, and brain. This leads to increased insulin sensitivity, slowed gastric emptying, appetite suppression, and enhanced satiety.
How It Works
Semaglutide mimics the natural GLP-1 hormone, binding to receptors in the pancreas, stomach, and brain. This leads to increased insulin sensitivity, slowed gastric emptying, appetite suppression, and enhanced satiety.
Expected Results
Along with diet and exercise, patients achieved an average of 15% weight loss maintained over 2 years. The SELECT trial also demonstrated a 20% reduction in major cardiovascular events.
Common Side Effects
Nausea, vomiting, constipation, bloating, gas, gastritis, and fatigue — most common during initiation and dose escalation, typically improving over time.
Who Should Avoid
Individuals with personal or family history of Medullary Thyroid Cancer (MTC) or MEN2 Syndrome. Those who are pregnant, breastfeeding, or trying to conceive.
This information is for educational purposes only and does not replace medical advice from your physician. Individual results vary. Always discuss side effects, contraindications, and treatment options during your consultation.